헬릭스미스
Financials
Valuation Metrics
헬릭스미스's Market Cap is ₩1724B. At end of 2025 it was ₩2867B. Ranked #893 of 2,410 in KR market (top 37%), #417 of 1,631 on KOSDAQ (top 26%), #103 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 172.39B KRW | KR#893/2,410 Sec#103/231 |
| Revenue | 2.42B KRW | KR#2,368/2,410 Sec#211/231 |
| Net Income | -1.63B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 143.20B KRW | KR#1,543/2,410 Sec#119/231 |
| Net Assets | 141.52B KRW | KR#1,173/2,410 Sec#87/231 |
| Employees | 44 | KR#2,090/2,410 Sec#192/231 |
| Value | ||
| P/B | 1.21x | KR#1,694/2,410 Sec#113/231 |
| P/S | 70.86x | KR#2,376/2,410 Sec#206/231 |
| FCF Yield | -4.13% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -1.15% | KR#1,632/2,410 Sec#113/231 |
| ROA | -1.14% | KR#1,690/2,410 Sec#119/231 |
| Op. Margin | -389.76% | KR#2,345/2,410 Sec#198/231 |
| Revenue Growth | -51.40% | KR#2,283/2,410 Sec#204/231 |
| Earnings Growth | -129.96% | KR#1,183/2,410 Sec#76/231 |
| Financial Health | ||
| Debt Ratio | 1.18% | KR#4/2,410 Sec#3/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -7.11B KRW | KR#1,593/2,410 Sec#134/231 |
| Cash | 31.83B KRW | KR#977/2,410 Sec#65/231 |
| Current Ratio | 56.69x | KR#5/2,410 Sec#2/231 |
| Performance | ||
| 1Y Return | -29.81% | KR#1,321/2,410 Sec#97/231 |
| 1M Return | 0.68% | KR#544/2,410 Sec#58/231 |
| From 52W High | -62.65% | KR#1,763/2,410 Sec#147/231 |
| 1Y MDD | -70.38% | KR#1,972/2,410 Sec#168/231 |
| Trading | ||
| Volume | 97,120 shares | KR#708/2,410 Sec#73/231 |
| Trading Value | 358.6M KRW | KR#970/2,410 Sec#107/231 |
| Foreign Own. | 4.01% | KR#1,047/2,410 Sec#93/231 |
| Per Share | ||
| EPS | -35 KRW | KR—/2,410 Sec—/231 |
| BPS | 3,070 KRW | KR#1,857/2,410 Sec#140/231 |
Company Info
Established in 1996, this R&D company was listed on KOSDAQ in 2005. It possesses global biotech-level resources and capabilities spanning from candidate substance discovery to preclinical trials, analysis, and production. The company provides diverse platform-based services, leveraging its experience with US FDA Orphan Drug, Fast Track, and RMAT designations. Building on its new material development expertise, it conducts B2B businesses for health functional foods and premium cosmetics. Helixmith is headquartered in Gangseo-gu, Seoul.